相关实验视频
Updated: Jan 15, 2026

06:33
Production of Human CRISPR-Engineered CAR-T Cells
Published on: March 15, 2021
14.4K
一种基于CRISPR/Cas9技术用于固体瘤的早期记忆丰富的全基NKG2DCAR-T细胞疗法
Cristina Aparicio1,2, Mónica Queipo1, Marina Belver1
1Unit of Excellence Institute of Biomedicine and Molecular Genetics of Valladolid (IBGM), Higher Council for Scientific Research (CSIC)-University of Valladolid (UVA), 47003 Valladolid, Spain.
Cancers
|October 16, 2025
概括
一种新的全基NKG2DCAR-T细胞疗法针对多个瘤配体,克服了当前自身治疗方法的局限性. 用IL-7/IL-15/IL-21进行优化制造,可以为广泛的癌症治疗提供优质的CAR-T细胞.
科学领域:
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
- 细胞疗法细胞疗法
背景情况:
- 化学抗原受体 (CAR) -T细胞疗法在血液性恶性瘤中显示出前景.
- 自主性CAR-T疗法面临挑战:高成本,制造延迟和抗原阴性复发.
- 现有的CAR针对单抗原,限制了对多种或正在发展的瘤的疗效.
研究的目的:
- 开发一种具有广泛目标特异性的全基NKG2DCAR-T细胞疗法.
- 优化制造过程,以提高CAR-T细胞产品的特性.
- 解决自身的CAR-T细胞疗法的局限性.
主要方法:
- 利用多重CRISPR/Cas9来淘汰捐赠者T细胞中的TCR和HLA类I.
- 通过lentiviral转导引入了第二代NKG2D-CAR.
- 对过程优化进行互白素补充 (IL-2,IL-7/IL-15,IL-7/IL-15/IL-21) 的比较.
主要成果:
- 新型CAR-T细胞证明了对宫和结直肠癌细胞的有效性.
- 使用IL-7/IL-15/IL-21补充剂的制造产生了最佳的CAR-T细胞.
- 这一优化小组表现出优异的遗传修饰,增殖,抗瘤活性和干细胞记忆T细胞子集比例.
结论:
- 开发了一个有前途的全基NKG2DCAR-T细胞疗法原型.
- 这种疗法针对多个配体,为各种瘤类型提供广泛的适用性.
- 优化制造提高了CAR-T细胞的持久性和有效性,为潜在的通用癌症治疗.
相关概念视频
CRISPR
57.5K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
57.5K
CRISPR/Cas9 Genome Editing
1.7K
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
1.7K

